Study design and patient characteristics
The study analyzed data from two consecutive cohorts of patients. It included 37 eyes of 21 patients treated with bevacizumab (0.25 mg/eye) from January 2012 to June 2015 and 27 eyes of 14 patients treated with ranibizumab (0.25 mg/eye) between July 2015 and July 2016.
The indications for anti-VEGF therapy varied. In 35 eyes, anti-VEGF was injected as salvage therapy, 17 eyes received anti-VEGF injection as an adjunct to vitrectomy, and only 12 eyes in the study received the anti-VEGF injection as monotherapy.
“In Japan, we still consider laser as first-line treatment,” Dr. Kusaka explained.
All of the infants were outborn. The two groups were similar in their baseline characteristics. Overall follow-up ranged from 3 to 65 months, but the mean follow-up was significantly longer for the bevacizumab group than for the ranibizumab-treated eyes (11 versus 39 months).